3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
186
Lymphoma, Large B-Cell, Diffuse
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Recurrence
28
Neoplasms, Plasma Cell
27
Lymphoma
25
Lymphoma, Mantle-Cell
23
Lymphoma, Follicular
23
Leukemia
20
Lymphoma, B-Cell, Marginal Zone
15
Lymphoma, Non-Hodgkin
14
Leukemia, Myeloid, Acute
13
Smoldering Multiple Myeloma
9
Myelodysplastic Syndromes
9
Lymphoma, T-Cell, Peripheral
7
Lymphoma, B-Cell
7
Waldenstrom Macroglobulinemia
6
Neoplasms
6
Neoplasm, Residual
6
Immunoglobulin Light-chain Amyloidosis
6
Lymphoma, T-Cell
5
Leukemia, Plasma Cell
5
Leukemia, Myelomonocytic, Chronic
5
Renal Insufficiency
4
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell, Cutaneous
4
Hodgkin Disease
4
Hematologic Diseases
4
Sezary Syndrome
3
Interventions
Prednisone
3
pembrolizumab
2
Melphalan
2
Cytarabine
2
venetoclax
1
ofatumumab
1
obinutuzumab
1
ioflupane
1
imetelstat
1
ibrutinib
1
gossypol acetic acid
1
gilteritinib
1
fluorocholine
1
fluciclovine F-18
1
deltacortene
1
daratumumab
1
aflibercept
1
abiraterone
1
Temozolomide
1
Self-Management
1
Quality of Life
1
Professional Autonomy
1
Paclitaxel
1
Oncolytic Virotherapy
1
Octreotide
1
Mitoxantrone
1
Methylene Blue
1
Lenalidomide
1
Gemtuzumab
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease
×
Lenalidomide
×
Clear all
NCT01160107
2023-06-29
RP_MPR
Fondazione EMN Italy Onlus
Phase 2
Completed
46 enrolled